guest ::
| Home > Publications database > First-line therapy with Bendamustine/Prednisone/Bortezomib (BPV) - A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients. > print |
| Home > Publications database > First-line therapy with Bendamustine/Prednisone/Bortezomib (BPV) - A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients. > print |
| 001 | 153915 | ||
| 005 | 20240229123053.0 | ||
| 024 | 7 | _ | |a 10.1111/ejh.13409 |2 doi |
| 024 | 7 | _ | |a pmid:32155662 |2 pmid |
| 024 | 7 | _ | |a 0036-553X |2 ISSN |
| 024 | 7 | _ | |a 0902-4441 |2 ISSN |
| 024 | 7 | _ | |a 1600-0609 |2 ISSN |
| 024 | 7 | _ | |a altmetric:77332888 |2 altmetric |
| 037 | _ | _ | |a DKFZ-2020-00525 |
| 041 | _ | _ | |a eng |
| 082 | _ | _ | |a 610 |
| 100 | 1 | _ | |a Knauf, Wolfgang |b 0 |
| 245 | _ | _ | |a First-line therapy with Bendamustine/Prednisone/Bortezomib (BPV) - A GMMG trial for non-transplant eligible symptomatic multiple myeloma patients. |
| 260 | _ | _ | |a Oxford |c 2020 |b Wiley-Blackwell |
| 336 | 7 | _ | |a article |2 DRIVER |
| 336 | 7 | _ | |a Output Types/Journal article |2 DataCite |
| 336 | 7 | _ | |a Journal Article |b journal |m journal |0 PUB:(DE-HGF)16 |s 1598860541_25230 |2 PUB:(DE-HGF) |
| 336 | 7 | _ | |a ARTICLE |2 BibTeX |
| 336 | 7 | _ | |a JOURNAL_ARTICLE |2 ORCID |
| 336 | 7 | _ | |a Journal Article |0 0 |2 EndNote |
| 500 | _ | _ | |a 2020 Aug;105(2):116-125 |
| 520 | _ | _ | |a The German-speaking Myeloma Multicenter Group (GMMG) conducted this trial to investigate efficacy and safety of the 3-drug-combination bendamustine/prednisone/bortezomib (BPV) as first-line therapy for elderly patients with multiple myeloma (MM).Elderly MM patients requiring first-line therapy and not eligible for intensive treatment were enrolled in this phase IIb multicenter study. Patients were treated with BPV regimen for a maximum of 9 cycles.46 patients were included into the trial with a median age of 76 years. 19 patients had renal impairment at baseline. The ORR was 76.5%, the median progression free survival 25 months and overall survival at 24 month 83.3%. The clinical benefit rate (CBR) including MR was 91.2%. In patients with renal impairment at baseline a renal response was observed in 11 pts. with complete recovery of the renal function in 6 patients. The most frequent CTC grade 3/4 AEs experienced by patients were hematological (17.5%) and infectious (9.8%) complications. No new safety signals were observed for the study drugs under investigation.BPV may serve as a first-line regimen for transplant ineligible elderly MM patients in particular for patients with renal impairment requiring a fast and durable renal response. |
| 536 | _ | _ | |a 313 - Cancer risk factors and prevention (POF3-313) |0 G:(DE-HGF)POF3-313 |c POF3-313 |f POF III |x 0 |
| 588 | _ | _ | |a Dataset connected to CrossRef, PubMed, |
| 700 | 1 | _ | |a Dingeldein, Gerrit |b 1 |
| 700 | 1 | _ | |a Schlag, Rudolf |b 2 |
| 700 | 1 | _ | |a Welslau, Manfred |b 3 |
| 700 | 1 | _ | |a Moehler, Thomas |0 0000-0003-1495-8917 |b 4 |
| 700 | 1 | _ | |a Terzer, Tobias |0 P:(DE-He78)9c4af0f5ceb3a2072b3736274eadf20e |b 5 |
| 700 | 1 | _ | |a Walter, Sarah |b 6 |
| 700 | 1 | _ | |a Goldschmidt, Hartmut |b 7 |
| 700 | 1 | _ | |a Raab, Marc-Steffen |b 8 |
| 700 | 1 | _ | |a group, BPV trial |0 P:(DE-HGF)0 |b 9 |
| 773 | _ | _ | |a 10.1111/ejh.13409 |g p. ejh.13409 |0 PERI:(DE-600)2027114-1 |n 2 |p 116-125 |t European journal of haematology |v 105 |y 2020 |x 1600-0609 |
| 909 | C | O | |o oai:inrepo02.dkfz.de:153915 |p VDB |
| 910 | 1 | _ | |a Deutsches Krebsforschungszentrum |0 I:(DE-588b)2036810-0 |k DKFZ |b 5 |6 P:(DE-He78)9c4af0f5ceb3a2072b3736274eadf20e |
| 913 | 1 | _ | |a DE-HGF |l Krebsforschung |1 G:(DE-HGF)POF3-310 |0 G:(DE-HGF)POF3-313 |2 G:(DE-HGF)POF3-300 |v Cancer risk factors and prevention |x 0 |4 G:(DE-HGF)POF |3 G:(DE-HGF)POF3 |b Gesundheit |
| 914 | 1 | _ | |y 2020 |
| 915 | _ | _ | |a JCR |0 StatID:(DE-HGF)0100 |2 StatID |b EUR J HAEMATOL : 2017 |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0200 |2 StatID |b SCOPUS |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0300 |2 StatID |b Medline |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0310 |2 StatID |b NCBI Molecular Biology Database |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0600 |2 StatID |b Ebsco Academic Search |
| 915 | _ | _ | |a Peer Review |0 StatID:(DE-HGF)0030 |2 StatID |b ASC |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0199 |2 StatID |b Clarivate Analytics Master Journal List |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0110 |2 StatID |b Science Citation Index |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)0150 |2 StatID |b Web of Science Core Collection |
| 915 | _ | _ | |a WoS |0 StatID:(DE-HGF)0111 |2 StatID |b Science Citation Index Expanded |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1110 |2 StatID |b Current Contents - Clinical Medicine |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1030 |2 StatID |b Current Contents - Life Sciences |
| 915 | _ | _ | |a DBCoverage |0 StatID:(DE-HGF)1050 |2 StatID |b BIOSIS Previews |
| 915 | _ | _ | |a IF < 5 |0 StatID:(DE-HGF)9900 |2 StatID |
| 920 | 1 | _ | |0 I:(DE-He78)C060-20160331 |k C060 |l C060 Biostatistik |x 0 |
| 980 | _ | _ | |a journal |
| 980 | _ | _ | |a VDB |
| 980 | _ | _ | |a I:(DE-He78)C060-20160331 |
| 980 | _ | _ | |a UNRESTRICTED |
| Library | Collection | CLSMajor | CLSMinor | Language | Author |
|---|